Header Logo

Connection

MANJUSHA GAGLANI to United States

Back to Details
This is a "connection" page, showing publications MANJUSHA GAGLANI has written about United States.
MANJUSHA GAGLANI
Connection Strength
1.885
United States
  1. Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial. Clin Infect Dis. 2023 02 08; 76(3):e1168-e1176.
    View in: PubMed
    Score: 0.073
  2. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 18; 71(11):422-428.
    View in: PubMed
    Score: 0.069
  3. Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011-2012 to 2016-2017. Clin Infect Dis. 2021 04 08; 72(7):1147-1157.
    View in: PubMed
    Score: 0.065
  4. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 02; 70(13):495-500.
    View in: PubMed
    Score: 0.064
  5. Reply to Yager and Doll. Clin Infect Dis. 2020 12 15; 71(12):3264-3265.
    View in: PubMed
    Score: 0.063
  6. Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. J Infect Dis. 2016 May 15; 213(10):1546-56.
    View in: PubMed
    Score: 0.045
  7. Vaccine effectiveness against influenza-associated hospitalizations in adults with liver disease, 2015-2020: US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). Hum Vaccin Immunother. 2025 Dec; 21(1):2457205.
    View in: PubMed
    Score: 0.021
  8. Protection From COVID-19 Vaccination and Prior SARS-CoV-2 Infection Among Children Aged 6 Months-4 Years, United States, September 2022-April 2023. J Pediatric Infect Dis Soc. 2025 Jan 20; 14(1).
    View in: PubMed
    Score: 0.021
  9. Reduced Effectiveness of Repeat Influenza Vaccination: Distinguishing Among Within-Season Waning, Recent Clinical Infection, and Subclinical Infection. J Infect Dis. 2024 Dec 16; 230(6):1309-1318.
    View in: PubMed
    Score: 0.021
  10. Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses - IVY Network, September 1, 2022-March 30, 2023. Vaccine. 2025 Jan 01; 43(Pt 2):126492.
    View in: PubMed
    Score: 0.021
  11. Effectiveness of Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Hospitalization and Severe In-Hospital Outcomes Among Adults in the United States, September 2022-August 2023. Influenza Other Respir Viruses. 2024 Nov; 18(11):e70027.
    View in: PubMed
    Score: 0.021
  12. Anti-SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021-June 2022. J Infect Dis. 2024 Jul 25; 230(1):45-54.
    View in: PubMed
    Score: 0.020
  13. Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023. J Infect Dis. 2024 Jul 25; 230(1):141-151.
    View in: PubMed
    Score: 0.020
  14. Effectiveness of the influenza vaccine for preventing laboratory-confirmed influenza infections in outpatient immunocompromised adults, 2017-2018. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2354013.
    View in: PubMed
    Score: 0.020
  15. Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022-April 2023. Influenza Other Respir Viruses. 2024 Jun; 18(6):e13342.
    View in: PubMed
    Score: 0.020
  16. Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023. Clin Infect Dis. 2024 Apr 10; 78(4):1056-1064.
    View in: PubMed
    Score: 0.020
  17. Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults. JAMA Netw Open. 2024 04 01; 7(4):e244954.
    View in: PubMed
    Score: 0.020
  18. Vaccine Effectiveness Against Pediatric Influenza-A-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022-2023 Season: VISION Network. Clin Infect Dis. 2024 03 20; 78(3):746-755.
    View in: PubMed
    Score: 0.020
  19. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years. JAMA. 2024 02 06; 331(5):408-416.
    View in: PubMed
    Score: 0.020
  20. Work Attendance with Acute Respiratory Illness Before and During COVID-19 Pandemic, United States, 2018-2022. Emerg Infect Dis. 2023 Dec; 29(12):2442-2450.
    View in: PubMed
    Score: 0.019
  21. Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodies. Environ Res. 2023 Dec 15; 239(Pt 1):117297.
    View in: PubMed
    Score: 0.019
  22. Changing Severity and Epidemiology of Adults Hospitalized With Coronavirus Disease 2019 (COVID-19) in the United States After Introduction of COVID-19 Vaccines, March 2021-August 2022. Clin Infect Dis. 2023 08 22; 77(4):547-557.
    View in: PubMed
    Score: 0.019
  23. Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years - VISION Network, United States, July 2022-June 2023. MMWR Morb Mortal Wkly Rep. 2023 Aug 18; 72(33):886-892.
    View in: PubMed
    Score: 0.019
  24. Vaccine Effectiveness Against Influenza-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2021-2022 Season, VISION Network. J Infect Dis. 2023 07 14; 228(2):185-195.
    View in: PubMed
    Score: 0.019
  25. Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021-2022 Influenza Season. Clin Infect Dis. 2023 04 17; 76(8):1358-1363.
    View in: PubMed
    Score: 0.019
  26. Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022. Clin Infect Dis. 2023 03 21; 76(6):1030-1037.
    View in: PubMed
    Score: 0.018
  27. Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States. Clin Infect Dis. 2023 02 08; 76(3):e460-e468.
    View in: PubMed
    Score: 0.018
  28. Relationship between Telework Experience and Presenteeism during COVID-19 Pandemic, United States, March-November 2020. Emerg Infect Dis. 2023 02; 29(2):278-285.
    View in: PubMed
    Score: 0.018
  29. Burden of medically attended influenza infection and cases averted by vaccination - United States, 2016/17 through 2018/19 influenza seasons. Vaccine. 2022 12 12; 40(52):7703-7708.
    View in: PubMed
    Score: 0.018
  30. Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States. Vaccine. 2022 11 15; 40(48):6979-6986.
    View in: PubMed
    Score: 0.018
  31. Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022. MMWR Morb Mortal Wkly Rep. 2022 Oct 21; 71(42):1327-1334.
    View in: PubMed
    Score: 0.018
  32. Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers. JAMA. 2022 10 18; 328(15):1523-1533.
    View in: PubMed
    Score: 0.018
  33. Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study. BMJ. 2022 10 11; 379:e072065.
    View in: PubMed
    Score: 0.018
  34. Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States. Clin Infect Dis. 2022 10 03; 75(Suppl 2):S159-S166.
    View in: PubMed
    Score: 0.018
  35. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States. JAMA Netw Open. 2022 09 01; 5(9):e2233273.
    View in: PubMed
    Score: 0.018
  36. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022. MMWR Morb Mortal Wkly Rep. 2022 Jul 22; 71(29):931-939.
    View in: PubMed
    Score: 0.018
  37. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States. Clin Infect Dis. 2022 05 03; 74(9):1515-1524.
    View in: PubMed
    Score: 0.017
  38. Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 25; 71(12):459-465.
    View in: PubMed
    Score: 0.017
  39. Interim Estimates of 2021-22 Seasonal Influenza Vaccine Effectiveness - United States, February 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 11; 71(10):365-370.
    View in: PubMed
    Score: 0.017
  40. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022 03 09; 376:e069761.
    View in: PubMed
    Score: 0.017
  41. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 04; 71(9):352-358.
    View in: PubMed
    Score: 0.017
  42. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18; 71(7):255-263.
    View in: PubMed
    Score: 0.017
  43. Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 28; 71(4):118-124.
    View in: PubMed
    Score: 0.017
  44. Clinical Influenza Testing Practices in Hospitalized Children at United States Medical Centers, 2015-2018. J Pediatric Infect Dis Soc. 2022 Jan 27; 11(1):5-8.
    View in: PubMed
    Score: 0.017
  45. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Jan 21; 71(4):139-145.
    View in: PubMed
    Score: 0.017
  46. Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January-September 2021. Am J Transplant. 2022 01; 22(1):306-314.
    View in: PubMed
    Score: 0.017
  47. Coronavirus disease 2019 (COVID-19) Versus Influenza in Hospitalized Adult Patients in the United States: Differences in Demographic and Severity Indicators. Clin Infect Dis. 2021 12 16; 73(12):2240-2247.
    View in: PubMed
    Score: 0.017
  48. Effect of Antigenic Drift on Influenza Vaccine Effectiveness in the United States-2019-2020. Clin Infect Dis. 2021 12 06; 73(11):e4244-e4250.
    View in: PubMed
    Score: 0.017
  49. Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Immunocompromised Adults. Clin Infect Dis. 2021 12 06; 73(11):e4353-e4360.
    View in: PubMed
    Score: 0.017
  50. Messenger RNA Vaccine Effectiveness Against Coronavirus Disease 2019 Among Symptomatic Outpatients Aged =16 Years in the United States, February-May 2021. J Infect Dis. 2021 11 22; 224(10):1694-1698.
    View in: PubMed
    Score: 0.017
  51. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
    View in: PubMed
    Score: 0.017
  52. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021. MMWR Morb Mortal Wkly Rep. 2021 Sep 24; 70(38):1337-1343.
    View in: PubMed
    Score: 0.017
  53. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med. 2021 10 07; 385(15):1355-1371.
    View in: PubMed
    Score: 0.017
  54. Influenza Vaccine Effectiveness Against Hospitalization in the United States, 2019-2020. J Infect Dis. 2021 09 01; 224(5):813-820.
    View in: PubMed
    Score: 0.017
  55. Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance - Eight U.S. Locations, December 2020-August 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 27; 70(34):1167-1169.
    View in: PubMed
    Score: 0.017
  56. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 27; 70(34):1156-1162.
    View in: PubMed
    Score: 0.017
  57. Waning Vaccine Effectiveness Against Influenza-Associated Hospitalizations Among Adults, 2015-2016 to 2018-2019, United States Hospitalized Adult Influenza Vaccine Effectiveness Network. Clin Infect Dis. 2021 08 16; 73(4):726-729.
    View in: PubMed
    Score: 0.017
  58. Influenza Vaccine Effectiveness in Inpatient and Outpatient Settings in the United States, 2015-2018. Clin Infect Dis. 2021 08 02; 73(3):386-392.
    View in: PubMed
    Score: 0.016
  59. Effects of Prior Season Vaccination on Current Season Vaccine Effectiveness in the United States Flu Vaccine Effectiveness Network, 2012-2013 Through 2017-2018. Clin Infect Dis. 2021 08 02; 73(3):497-505.
    View in: PubMed
    Score: 0.016
  60. Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States. Vaccine. 2021 06 08; 39(25):3324-3328.
    View in: PubMed
    Score: 0.016
  61. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged =65 Years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021 May 07; 70(18):674-679.
    View in: PubMed
    Score: 0.016
  62. Differences between Frequentist and Bayesian inference in routine surveillance for influenza vaccine effectiveness: a test-negative case-control study. BMC Public Health. 2021 03 16; 21(1):516.
    View in: PubMed
    Score: 0.016
  63. Relative and Absolute Effectiveness of High-Dose and Standard-Dose Influenza Vaccine Against Influenza-Related Hospitalization Among Older Adults-United States, 2015-2017. Clin Infect Dis. 2021 03 15; 72(6):995-1003.
    View in: PubMed
    Score: 0.016
  64. Influenza vaccination coverage among persons seeking outpatient medical care for acute respiratory illness in five states in the United States, 2011-2012 through 2018-2019. Vaccine. 2021 03 19; 39(12):1788-1796.
    View in: PubMed
    Score: 0.016
  65. Reducing Antibiotic Use in Ambulatory Care Through Influenza Vaccination. Clin Infect Dis. 2020 12 31; 71(11):e726-e734.
    View in: PubMed
    Score: 0.016
  66. Patterns of Influenza Vaccination and Vaccine Effectiveness Among Young US Children Who Receive Outpatient Care for Acute Respiratory Tract Illness. JAMA Pediatr. 2020 07 01; 174(7):705-713.
    View in: PubMed
    Score: 0.015
  67. Influenza vaccine effectiveness among outpatients in the US Influenza Vaccine Effectiveness Network by study site 2011-2016. Influenza Other Respir Viruses. 2020 07; 14(4):380-390.
    View in: PubMed
    Score: 0.015
  68. Interim Estimates of 2019-20 Seasonal Influenza Vaccine Effectiveness - United States, February 2020. MMWR Morb Mortal Wkly Rep. 2020 Feb 21; 69(7):177-182.
    View in: PubMed
    Score: 0.015
  69. Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018-2019 Season. J Infect Dis. 2020 01 01; 221(1):8-15.
    View in: PubMed
    Score: 0.015
  70. Paid Leave and Access to Telework as Work Attendance Determinants during Acute Respiratory Illness, United States, 2017-2018. Emerg Infect Dis. 2020 01; 26(1).
    View in: PubMed
    Score: 0.015
  71. Effects of Influenza Vaccination in the United States During the 2017-2018 Influenza Season. Clin Infect Dis. 2019 11 13; 69(11):1845-1853.
    View in: PubMed
    Score: 0.015
  72. Prevention of Influenza Hospitalization Among Adults in the United States, 2015-2016: Results From the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). J Infect Dis. 2019 09 13; 220(8):1265-1275.
    View in: PubMed
    Score: 0.014
  73. Influenza Vaccine Effectiveness in the United States During the 2016-2017 Season. Clin Infect Dis. 2019 05 17; 68(11):1798-1806.
    View in: PubMed
    Score: 0.014
  74. Influenza Vaccine Effectiveness and Statin Use Among Adults in the United States, 2011-2017. Clin Infect Dis. 2019 05 02; 68(10):1616-1622.
    View in: PubMed
    Score: 0.014
  75. Interim Estimates of 2018-19 Seasonal Influenza Vaccine Effectiveness - United States, February 2019. MMWR Morb Mortal Wkly Rep. 2019 Feb 15; 68(6):135-139.
    View in: PubMed
    Score: 0.014
  76. Hospitalization following outpatient medical care for influenza: US influenza vaccine effectiveness network, 2011-12-2015-16. Influenza Other Respir Viruses. 2019 03; 13(2):133-137.
    View in: PubMed
    Score: 0.014
  77. Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012-2016. Vaccine. 2018 12 18; 36(52):8047-8053.
    View in: PubMed
    Score: 0.014
  78. Influence of Birth Cohort on Effectiveness of 2015-2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States. J Infect Dis. 2018 06 20; 218(2):189-196.
    View in: PubMed
    Score: 0.013
  79. Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons. JAMA Netw Open. 2018 06 01; 1(2):e180243.
    View in: PubMed
    Score: 0.013
  80. Influenza Antiviral Prescribing for Outpatients With an Acute Respiratory Illness and at High Risk for Influenza-Associated Complications During 5 Influenza Seasons-United States, 2011-2016. Clin Infect Dis. 2018 03 19; 66(7):1035-1041.
    View in: PubMed
    Score: 0.013
  81. Influenza vaccine effectiveness in older adults compared with younger adults over five seasons. Vaccine. 2018 02 28; 36(10):1272-1278.
    View in: PubMed
    Score: 0.013
  82. Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018. MMWR Morb Mortal Wkly Rep. 2018 Feb 16; 67(6):180-185.
    View in: PubMed
    Score: 0.013
  83. 2015-2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States. Clin Infect Dis. 2018 02 10; 66(5):665-672.
    View in: PubMed
    Score: 0.013
  84. Burden of medically attended influenza infection and cases averted by vaccination - United States, 2013/14 through 2015/16 influenza seasons. Vaccine. 2018 01 25; 36(4):467-472.
    View in: PubMed
    Score: 0.013
  85. Influenza Vaccine Effectiveness in the United States during the 2015-2016 Season. N Engl J Med. 2017 08 10; 377(6):534-543.
    View in: PubMed
    Score: 0.013
  86. Prior-Season Vaccination and Risk of Influenza During the 2014-2015 Season in the United States. J Infect Dis. 2017 07 15; 216(2):284-285.
    View in: PubMed
    Score: 0.012
  87. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014-2015 season. Vaccine. 2017 05 09; 35(20):2685-2693.
    View in: PubMed
    Score: 0.012
  88. Interim Estimates of 2016-17 Seasonal Influenza Vaccine Effectiveness - United States, February 2017. MMWR Morb Mortal Wkly Rep. 2017 Feb 17; 66(6):167-171.
    View in: PubMed
    Score: 0.012
  89. 2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type. Clin Infect Dis. 2016 Dec 15; 63(12):1564-1573.
    View in: PubMed
    Score: 0.012
  90. Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015. J Infect Dis. 2016 10 01; 214(7):1010-9.
    View in: PubMed
    Score: 0.011
  91. Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 Months to 8 Years Old During 2011-2012 and 2012-2013: The Importance of Two Priming Doses. Pediatr Infect Dis J. 2016 Mar; 35(3):299-308.
    View in: PubMed
    Score: 0.011
  92. Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine. Pediatrics. 2016 Feb; 137(2):e20153279.
    View in: PubMed
    Score: 0.011
  93. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States. Vaccine. 2016 Jan 02; 34(1):77-82.
    View in: PubMed
    Score: 0.011
  94. Incidence of medically attended influenza infection and cases averted by vaccination, 2011/2012 and 2012/2013 influenza seasons. Vaccine. 2015 Sep 22; 33(39):5181-7.
    View in: PubMed
    Score: 0.011
  95. Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb Mortal Wkly Rep. 2015 Jan 16; 64(1):10-5.
    View in: PubMed
    Score: 0.010
  96. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015 May 15; 211(10):1529-40.
    View in: PubMed
    Score: 0.010
  97. Interim estimates of 2013-14 seasonal influenza vaccine effectiveness - United States, February 2014. MMWR Morb Mortal Wkly Rep. 2014 Feb 21; 63(7):137-42.
    View in: PubMed
    Score: 0.010
  98. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014 Feb; 58(3):319-27.
    View in: PubMed
    Score: 0.010
  99. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age. Pediatr Infect Dis J. 2011 Oct; 30(10):e179-85.
    View in: PubMed
    Score: 0.008
  100. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis. 2010 Mar 17; 10:71.
    View in: PubMed
    Score: 0.007
  101. Effectiveness of school-based influenza vaccination. N Engl J Med. 2006 Dec 14; 355(24):2523-32.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.